Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

The inflation-adjusted cost of developing a new drug now doubles roughly every nine years. To reverse this trend, the ...

Balasegaram is executive director of the Global Antibiotic Research & Development Partnership. No matter how carefully we use the antibiotics we have, drug resistant infections will continue to gain ...

In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...

OpenAI, the creator of ChatGPT, is pushing to introduce a business model that shares profits with companies achieving results ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...